.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,485,285

« Back to Dashboard

Details for Patent: 7,485,285

Title:Delivery of antidepressants through an inhalation route
Abstract: The present invention relates to the delivery of antidepressants through an inhalation route. Specifically, it relates to aerosols containing an antidepressant that are used in inhalation therapy. In a method aspect of the present invention, an antidepressant is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of an antidepressant, on a solid support, form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% antidepressant degradation products. In a kit aspect of the present invention, a kit for delivering an antidepressant through an inhalation route to a mammal is provided which comprises: a) a thin coating of an antidepressant composition and b) a device for dispensing said thin coating as a condensation aerosol.
Inventor(s): Rabinowitz; Joshua D (Princeton, NJ), Zaffaroni; Alejandro C (Atherton, CA)
Assignee: Alexza Pharmaceuticals, Inc. (Mountain View, CA)
Filing Date:Jun 13, 2006
Application Number:11/451,853
Claims:1. A condensation aerosol for delivery of bupropion formed by heating a composition containing bupropion coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of bupropion and less than 5 percent by weight of bupropion degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

2. The condensation aerosol according to claim 1, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

3. The condensation aerosol according to claim 1 or claim 2, wherein the geometric standard deviation around the MMAD is less than 3.0.

4. A condensation aerosol for delivery of nefazodone formed by heating a composition containing nefazodone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of nefazodone and less than 5 percent by weight of nefazodone degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

5. The condensation aerosol according to claim 4, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

6. The condensation aerosol according to claim 4 or claim 5, wherein the geometric standard deviation around the MMAD is less than 3.0.

7. A condensation aerosol for delivery of perphenazine formed by heating a composition containing perphenazine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of perphenazine and less than 5 percent by weight of perphenazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

8. The condensation aerosol according to claim 7, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

9. The condensation aerosol according to claim 7 or claim 8, wherein the geometric standard deviation around the MMAD is less than 3.0.

10. A condensation aerosol for delivery of trazodone formed by heating a composition containing trazodone coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of trazodone and less than 5 percent by weight of trazodone degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

11. The condensation aerosol according to claim 10, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

12. The condensation aerosol according to claim 10 or claim 11, wherein the geometric standard deviation around the MMAD is less than 3.0.

13. A condensation aerosol for delivery of trimipramine formed by heating a composition containing trimipramine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of trimipramine and less than 5 percent by weight of trimipramine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

14. The condensation aerosol according to claim 13, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

15. The condensation aerosol according to claim 13 or claim 14, wherein the geometric standard deviation around the MMAD is less than 3.0.

16. A condensation aerosol for delivery of venlafaxine formed by heating a composition containing venlafaxine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of venlafaxine and less than 5 percent by weight of venlafaxine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

17. The condensation aerosol according to claim 16, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

18. The condensation aerosol according to claim 16 or claim 17, wherein the geometric standard deviation around the MMAD is less than 3.0.

19. A condensation aerosol for delivery of tranylcypromine formed by heating a composition containing tranylcypromine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of tranylcypromine and less than 5 percent by weight of tranylcypromine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

20. The condensation aerosol according to claim 19, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

21. The condensation aerosol according to claim 19 or claim 20, wherein the geometric standard deviation around the MMAD is less than 3.0.

22. A condensation aerosol for delivery of citalopram formed by heating a composition containing citalopram coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of citalopram and less than 5 percent by weight of citalopram degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

23. The condensation aerosol according to claim 22, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

24. The condensation aerosol according to claim 22 or claim 23, wherein the geometric standard deviation around the MMAD is less than 3.0.

25. A condensation aerosol for delivery of fluoxetine formed by heating a composition containing fluoxetine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of fluoxetine and less than 5 percent by weight of fluoxetine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

26. The condensation aerosol according to claim 25, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

27. The condensation aerosol according to claim 25 or claim 26, wherein the geometric standard deviation around the MMAD is less than 3.0.

28. A condensation aerosol for delivery of fluvoxamine formed by heating a composition containing fluvoxamine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of fluvoxamine and less than 5 percent by weight of fluvoxamine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

29. The condensation aerosol according to claim 28, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

30. The condensation aerosol according to claim 28 or claim 29, wherein the geometric standard deviation around the MMAD is less than 3.0.

31. A condensation aerosol for delivery of mirtazepine formed by heating a composition containing mirtazepine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of mirtazepine and less than 5 percent by weight of mirtazepine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

32. The condensation aerosol according to claim 31, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

33. The condensation aerosol according to claim 31 or claim 32, wherein the geometric standard deviation around the MMAD is less than 3.0.

34. A condensation aerosol for delivery of paroxetine formed by heating a composition containing paroxetine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of paroxetine and less than 5 percent by weight of paroxetine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

35. The condensation aerosol according to claim 34, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

36. The condensation aerosol according to claim 34 or claim 35, wherein the geometric standard deviation around the MMAD is less than 3.0.

37. A condensation aerosol for delivery of sertraline formed by heating a composition containing sertraline coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of sertraline and less than 5 percent by weight of sertraline degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

38. The condensation aerosol according to claim 37, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

39. The condensation aerosol according to claim 37 or claim 38, wherein the geometric standard deviation around the MMAD is less than 3.0.

40. A condensation aerosol for delivery of amoxapine formed by heating a composition containing amoxapine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of amoxapine and less than 5 percent by weight of amoxapine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

41. The condensation aerosol according to claim 40, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

42. The condensation aerosol according to claim 40 or claim 41, wherein the geometric standard deviation around the MMAD is less than 3.0.

43. A condensation aerosol for delivery of clomipramine formed by heating a composition containing clomipramine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of clomipramine and less than 5 percent by weight of clomipramine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

44. The condensation aerosol according to claim 43, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

45. The condensation aerosol according to claim 43 or claim 44, wherein the geometric standard deviation around the MMAD is less than 3.0.

46. A condensation aerosol for delivery of doxepin formed by heating a composition containing doxepin coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of doxepin and less than 5 percent by weight of doxepin degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

47. The condensation aerosol according to claim 46, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

48. The condensation aerosol according to claim 46 or claim 47, wherein the geometric standard deviation around the MMAD is less than 3.0.

49. A condensation aerosol for delivery of imipramine formed by heating a composition containing imipramine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of imipramine and less than 5 percent by weight of imipramine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

50. The condensation aerosol according to claim 49, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

51. The condensation aerosol according to claim 49 or claim 50, wherein the geometric standard deviation around the MMAD is less than 3.0.

52. A condensation aerosol for delivery of maprotiline formed by heating a composition containing maprotiline coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of maprotiline and less than 5 percent by weight of maprotiline degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

53. The condensation aerosol according to claim 52, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

54. The condensation aerosol according to claim 52 or claim 53, wherein the geometric standard deviation around the MMAD is less than 3.0.

55. A condensation aerosol for delivery of nortriptyline formed by heating a composition containing nortriptyline coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of nortriptyline and less than 5 percent by weight of nortriptyline degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

56. The condensation aerosol according to claim 55, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

57. The condensation aerosol according to claim 55 or claim 56, wherein the geometric standard deviation around the MMAD is less than 3.0.

58. A condensation aerosol for delivery of valproic acid formed by heating a composition containing valproic acid coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of valproic acid and less than 5 percent by weight of valproic acid degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

59. The condensation aerosol according to claim 58, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

60. The condensation aerosol according to claim 58 or claim 59, wherein the geometric standard deviation around the MMAD is less than 3.0.

61. A condensation aerosol for delivery of protriptyline formed by heating a composition containing protriptyline coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of protriptyline and less than 5 percent by weight of protriptyline degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

62. The condensation aerosol according to claim 61, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

63. The condensation aerosol according to claim 61 or claim 62, wherein the geometric standard deviation around the MMAD is less than 3.0.

64. A method of forming a bupropion containing aerosol comprising: (a) heating a composition containing bupropion coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of bupropion degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

65. The method according to claim 64, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

66. The method according to claim 65, wherein the coated composition comprises at least 10 percent by weight of bupropion.

67. A method of forming a nefazodone containing aerosol comprising: (a) heating a composition containing nefazodone coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of nefazodone degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

68. The method according to claim 67, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

69. The method according to claim 68, wherein the coated composition comprises at least 10 percent by weight of nefazodone.

70. A method of forming a perphenazine containing aerosol comprising: (a) heating a composition containing perphenazine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of perphenazine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

71. The method according to claim 70, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

72. The method according to claim 71, wherein the coated composition comprises at least 10 percent by weight of perphenazine.

73. A method of forming a trazodone containing aerosol comprising: (a) heating a composition containing trazodone coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of trazodone degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

74. The method according to claim 73, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

75. The method according to claim 74, wherein the coated composition comprises at least 10 percent by weight of trazodone.

76. A method of forming a trimipramine containing aerosol comprising: (a) heating a composition containing trimipramine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of trimipramine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

77. The method according to claim 76, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

78. The method according to claim 77, wherein the coated composition comprises at least 10 percent by weight of trimipramine.

79. A method of forming a venlafaxine containing aerosol comprising: (a) heating a composition containing venlafaxine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of venlafaxine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

80. The method according to claim 79, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

81. The method according to claim 80, wherein the coated composition comprises at least 10 percent by weight of venlafaxine.

82. A method of forming a tranylcypromine containing aerosol comprising: (a) heating a composition containing tranylcypromine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of tranylcypromine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

83. The method according to claim 82, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

84. The method according to claim 83, wherein the coated composition comprises at least 10 percent by weight of tranylcypromine.

85. A method of forming a citalopram containing aerosol comprising: (a) heating a composition containing citalopram coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of citalopram degradation product, and the condensation aerosol has an MMAD of less than 5 microns.

86. The method according to claim 85, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

87. The method according to claim 86, wherein the coated composition comprises at least 10 percent by weight of citalopram.

88. A method of forming a fluoxetine containing aerosol comprising: (a) heating a composition containing fluoxetine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of fluoxetine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

89. The method according to claim 88, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

90. The method according to claim 89, wherein the coated composition comprises at least 10 percent by weight of fluoxetine.

91. A method of forming a fluvoxamine containing aerosol comprising: (a) heating a composition containing fluvoxamine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of fluvoxamine degradation product, and the condensation aerosol has an MMAD of less than 5 microns.

92. The method according to claim 91, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

93. The method according to claim 92, wherein the coated composition comprises at least 10 percent by weight of fluvoxamine.

94. A method of forming a mirtazepine containing aerosol comprising: (a) heating a composition containing mirtazepine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of mirtazepine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

95. The method according to claim 94, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

96. The method according to claim 95, wherein the coated composition comprises at least 10 percent by weight of mirtazepine.

97. A method of forming a paroxetine containing aerosol comprising: (a) heating a composition containing paroxetine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of paroxetine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

98. The method according to claim 97, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

99. The method according to claim 98, wherein the coated composition comprises at least 10 percent by weight of paroxetine.

100. A method of forming a sertraline containing aerosol comprising: (a) heating a composition containing sertraline coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of sertraline degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

101. The method according to claim 100, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

102. The method according to claim 101, wherein the coated composition comprises at least 10 percent by weight of sertraline.

103. A method of forming an amoxapine containing aerosol comprising: (a) heating a composition containing amoxapine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of amoxapine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

104. The method according to claim 103, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

105. The method according to claim 104, wherein the coated composition comprises at least 10 percent by weight of amoxapine.

106. A method of forming a clomipramine containing aerosol comprising: (a) heating a composition containing clomipramine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of clomipramine degradation product, and the condensation aerosol has an MMAD of less than 5 microns.

107. The method according to claim 106, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

108. The method according to claim 107, wherein the coated composition comprises at least 10 percent by weight of clomipramine.

109. A method of forming a doxepin containing aerosol comprising: (a) heating a composition containing doxepin coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of doxepin degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

110. The method according to claim 109, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

111. The method according to claim 110, wherein the coated composition comprises at least 10 percent by weight of doxepin.

112. A method of forming an imipramine containing aerosol comprising: (a) heating a composition containing imipramine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of imipramine degradation product, and the condensation aerosol has an MMAD of less than 5 microns.

113. The method according to claim 112, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

114. The method according to claim 113, wherein the coated composition comprises at least 10 percent by weight of imipramine.

115. A method of forming a maprotiline containing aerosol comprising: (a) heating a composition containing maprotiline coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of maprotiline degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

116. The method according to claim 115, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

117. The method according to claim 116, wherein the coated composition comprises at least 10 percent by weight of maprotiline.

118. A method of forming a nortriptyline containing aerosol comprising: (a) heating a composition containing nortriptyline coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of nortriptyline degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

119. The method according to claim 118, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

120. The method according to claim 119, wherein the coated composition comprises at least 10 percent by weight of nortriptyline.

121. A method of forming a valproic acid containing aerosol comprising: (a) heating a composition containing valproic acid coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of valproic acid degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

122. The method according to claim 121, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

123. The method according to claim 122, wherein the coated composition comprises at least 10 percent by weight of valproic acid.

124. A method of forming a protriptyline containing aerosol comprising: (a) heating a composition containing protriptyline coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of protriptyline degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

125. The method according to claim 124, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

126. The method according to claim 125, wherein the coated composition comprises at least 10 percent by weight of protriptyline.

127. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortriptyline, valproic acid, and protriptyline, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

128. The method according to claim 127, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

129. The method according to claim 128, wherein the coated composition comprises at least 10 percent by weight of the drug.

130. A method of forming a drug containing aerosol comprising: (a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortriptyline, valproic acid, and protriptyline, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

131. The method according to claim 130, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

132. The method according to claim 131, wherein the coated composition comprises at least 10 percent by weight of the salt form of the drug.

133. The condensation aerosol according to claim 2, wherein the condensing comprises allowing the vapor to cool.

134. The condensation aerosol according to claim 5, wherein the condensing comprises allowing the vapor to cool.

135. The condensation aerosol according to claim 8, wherein the condensing comprises allowing the vapor to cool.

136. The condensation aerosol according to claim 11, wherein the condensing comprises allowing the vapor to cool.

137. The condensation aerosol according to claim 14, wherein the condensing comprises allowing the vapor to cool.

138. The condensation aerosol according to claim 17, wherein the condensing comprises allowing the vapor to cool.

139. The condensation aerosol according to claim 20, wherein the condensing comprises allowing the vapor to cool.

140. The condensation aerosol according to claim 23, wherein the condensing comprises allowing the vapor to cool.

141. The condensation aerosol according to claim 26, wherein the condensing comprises allowing the vapor to cool.

142. The condensation aerosol according to claim 29, wherein the condensing comprises allowing the vapor to cool.

143. The condensation aerosol according to claim 32, wherein the condensing comprises allowing the vapor to cool.

144. The condensation aerosol according to claim 35, wherein the condensing comprises allowing the vapor to cool.

145. The condensation aerosol according to claim 38, wherein the condensing comprises allowing the vapor to cool.

146. The condensation aerosol according to claim 41, wherein the condensing comprises allowing the vapor to cool.

147. The condensation aerosol according to claim 44, wherein the condensing comprises allowing the vapor to cool.

148. The condensation aerosol according to claim 47, wherein the condensing comprises allowing the vapor to cool.

149. The condensation aerosol according to claim 50, wherein the condensing comprises allowing the vapor to cool.

150. The condensation aerosol according to claim 53, wherein the condensing comprises allowing the vapor to cool.

151. The condensation aerosol according to claim 56, wherein the condensing comprises allowing the vapor to cool.

152. The condensation aerosol according to claim 59, wherein the condensing comprises allowing the vapor to cool.

153. The condensation aerosol according to claim 62, wherein the condensing comprises allowing the vapor to cool.

154. The method according to claim 65, wherein the condensing comprises allowing the vapor to cool.

155. The method according to claim 68, wherein the condensing comprises allowing the vapor to cool.

156. The method according to claim 71, wherein the condensing comprises allowing the vapor to cool.

157. The method according to claim 74, wherein the condensing comprises allowing the vapor to cool.

158. The method according to claim 77, wherein the condensing comprises allowing the vapor to cool.

159. The method according to claim 80, wherein the condensing comprises allowing the vapor to cool.

160. The method according to claim 83, wherein the condensing comprises allowing the vapor to cool.

161. The method according to claim 86, wherein the condensing comprises allowing the vapor to cool.

162. The method according to claim 89, wherein the condensing comprises allowing the vapor to cool.

163. The method according to claim 92, wherein the condensing comprises allowing the vapor to cool.

164. The method according to claim 95, wherein the condensing comprises allowing the vapor to cool.

165. The method according to claim 98, wherein the condensing comprises allowing the vapor to cool.

166. The method according to claim 101, wherein the condensing comprises allowing the vapor to cool.

167. The method according to claim 104, wherein the condensing comprises allowing the vapor to cool.

168. The method according to claim 107, wherein the condensing comprises allowing the vapor to cool.

169. The method according to claim 110, wherein the condensing comprises allowing the vapor to cool.

170. The method according to claim 113, wherein the condensing comprises allowing the vapor to cool.

171. The method according to claim 116, wherein the condensing comprises allowing the vapor to cool.

172. The method according to claim 119, wherein the condensing comprises allowing the vapor to cool.

173. The method according to claim 122, wherein the condensing comprises allowing the vapor to cool.

174. The method according to claim 125, wherein the condensing comprises allowing the vapor to cool.

175. The method according to claim 128, wherein the condensing comprises allowing the vapor to cool.

176. The method according to claim 131, wherein the condensing comprises allowing the vapor to cool.

177. A method of forming a drug containing aerosol comprising: (a) heating a composition containing the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of bupropion, nefazodone, perphenazine, trazodone, trimipramine, venlafaxine, tranylcypromine, citalopram, fluoxetine, fluvoxamine, mirtazepine, paroxetine, sertraline, amoxapine, clomipramine, doxepin, imipramine, maprotiline, nortriptyline, valproic acid, and protriptyline, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns.

178. The method according to claim 177, wherein the condensation aerosol has an MMAD of 0.2 to 3 microns.

179. The method according to claim 178, wherein the condensation aerosol is formed at a rate greater than 0.75 mg/second.

180. The method according to claim 179, wherein the condensation aerosol is formed at a rate greater than 1 mg/second.

181. The method according to claim 180, wherein the condensation aerosol is formed at a rate greater than 2 mg/second.

182. The method according to claim 177, wherein the condensing comprises allowing the vapor to cool.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc